Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Su-Chun Cheng

Showing results (61-70 of 73) with videos related to

Pageof 8
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 29, 2022
A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor-Positive Recurrent Endometrial CancerPanagiotis A Konstantinopoulos, Elizabeth K Lee, Niya Xiong, et al.
JCO Precision Oncology|April 10, 2025
Serial Circulating Tumor DNA Sequencing to Monitor Response and Define Acquired Resistance to Letrozole/Abemaciclib in Endometrial CancerPanagiotis A Konstantinopoulos, Mingyang Cai, Elizabeth K Lee, et al.
Nature Communications|September 23, 2021
A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancerPanagiotis A Konstantinopoulos, Alexandre André B A da Costa, Doga Gulhan, et al.
Nature Communications|December 3, 2025
Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trialPanagiotis A Konstantinopoulos, Ningxuan Zhou, Richard T Penson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2022
Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian CancerMin Liu, Nabihah Tayob, Livius Penter, et al.
JAMA Oncology|July 28, 2022
Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial CancerPanagiotis A Konstantinopoulos, Allison A Gockley, Niya Xiong, et al.
JCO Precision Oncology|April 18, 2024
Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker AnalysesPanagiotis A Konstantinopoulos, Su-Chun Cheng, Elizabeth K Lee, et al.
Gynecologic Oncology|May 17, 2024
A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparibJoyce F Liu, Niya Xiong, Robert M Wenham, et al.
British Journal of Cancer|December 10, 2021
Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumoursPanagiotis A Konstantinopoulos, Su-Chun Cheng, Jeffrey G Supko, et al.
Journal of the American Medical Informatics Association : JAMIA|March 14, 2024
Centralized Interactive Phenomics Resource: an integrated online phenomics knowledgebase for health data usersJacqueline Honerlaw, Yuk-Lam Ho, Francesca Fontin, et al.
Pageof 8

Showing results (61-70 of 73) with videos related to

Sort By:
Pageof 8
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 29, 2022
A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor-Positive Recurrent Endometrial CancerPanagiotis A Konstantinopoulos, Elizabeth K Lee, Niya Xiong, et al.
JCO Precision Oncology|April 10, 2025
Serial Circulating Tumor DNA Sequencing to Monitor Response and Define Acquired Resistance to Letrozole/Abemaciclib in Endometrial CancerPanagiotis A Konstantinopoulos, Mingyang Cai, Elizabeth K Lee, et al.
Nature Communications|September 23, 2021
A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancerPanagiotis A Konstantinopoulos, Alexandre André B A da Costa, Doga Gulhan, et al.
Nature Communications|December 3, 2025
Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trialPanagiotis A Konstantinopoulos, Ningxuan Zhou, Richard T Penson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2022
Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian CancerMin Liu, Nabihah Tayob, Livius Penter, et al.
JAMA Oncology|July 28, 2022
Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial CancerPanagiotis A Konstantinopoulos, Allison A Gockley, Niya Xiong, et al.
JCO Precision Oncology|April 18, 2024
Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker AnalysesPanagiotis A Konstantinopoulos, Su-Chun Cheng, Elizabeth K Lee, et al.
Gynecologic Oncology|May 17, 2024
A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparibJoyce F Liu, Niya Xiong, Robert M Wenham, et al.
British Journal of Cancer|December 10, 2021
Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumoursPanagiotis A Konstantinopoulos, Su-Chun Cheng, Jeffrey G Supko, et al.
Journal of the American Medical Informatics Association : JAMIA|March 14, 2024
Centralized Interactive Phenomics Resource: an integrated online phenomics knowledgebase for health data usersJacqueline Honerlaw, Yuk-Lam Ho, Francesca Fontin, et al.
Pageof 8